A Head to Head Comparison Between SurgiMend® – Fetal Bovine Acellular Dermal Matrix and Tutomesh® – A Bovine Pericardium Collagen Membrane in Breast Reconstruction in 45 Cases

doi:10.21873/invivo.11112

Cited by 14 publications

(7 citation statements)

References 19 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, factors such as a decrease in the donor site morbidity, more cost-effective surgical procedures and improved implant materials play an important role in the general shift towards implant-based reconstruction. In addition to simply using an implant, overall cosmetic outcome may also be improved by using ADMs or synthetic meshes for implant stabilization (6)(7)(8)(9)(10). Over the past decades we have seen a steep increase in the use of ADMs in epi-pectoral and sup-pectoral implant driven breast reconstruction and recent meta-analyses showed the use of ADM's to be particularly beneficial in reducing implant malrotation/malpositioning and capsular contracture (11)(12)(13).…”

mentioning

confidence: 99%

A Retrospective Head-to-head Comparison Between TiLoop Bra/TiMesh® and Seragyn® in 320 Cases of Reconstructive Breast Surgery

et al. 2019

View full text Add to dashboard Cite

Background/Aim: Clinical data concerning synthetic meshes in comparison to acellular dermal matrices (ADMs) in breast reconstruction are limited. Also, direct comparisons between titanium-coated polypropylene mesh and partially absorbable polypropylene mesh have not yet been reported. Materials and Methods: This analysis represents a retrospective, single-surgeon, multi-center study of 320 cases using either TiLoop Bra/TiMesh ® (n=192) or Seragyn ® (n=128) in breast reconstruction. Results were compared with ADM-based reconstructions (Epiflex ® and SurgiMend ® ). Results: Major complication rates (i.e. revision surgery) occurred in 3.9% (Seragyn ® ) and 8.3% (TiLoop Bra/TiMesh ® ) of all cases. Minor complications occurred in 18% (Seragyn ® ) and 8.9% (TiLoop Bra/TiMesh ® ). Subgroup analysis showed red breast syndrome to occur more often in the Seragyn group (3.9% Seragyn ® vs. 0.5% TiLoop Bra/TiMesh ® , p<0.05). Conclusion: TiLoop Bra/TiMesh ® and Seragyn ® do not differ significantly in complication rates. There was no difference in performance when compared to ADMs. Materials and MethodsThis work evaluated a multicenter, single surgeon experience over the course of 14 years with a total of 320 cases (Seragyn ® , n=128; TiLoop Bra/TiMesh ® , n=192) (Figure 1

show abstract

mentioning

confidence: 99%

A Retrospective Head-to-head Comparison Between TiLoop Bra/TiMesh® and Seragyn® in 320 Cases of Reconstructive Breast Surgery

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Thirty-four women were included in the study. The mean age was 42 years (SD 8.6; range 23-58), and the mean BMI was 23.5 (SD 2.5; range [19][20][21][22][23][24][25][26][27][28][29][30]. Eight breasts had previously undergone augmentation or mastopexy.…”

Section: Resultsmentioning

confidence: 99%

A Long-term Evaluation of Acellular Dermal Matrix for Immediate Implant-based Breast Reconstruction following Risk-reducing Mastectomy

Khan,

Wickman,

Schultz

2024

Plastic and Reconstructive Surgery - Global Open

View full text Add to dashboard Cite

Background: Acellular dermal matrices (ADMs) are sometimes used in implant-based breast reconstructions (IBR), but long-term ADM-related evaluations are scarce. In this study, we evaluated early and late complications and patient-related outcomes (PROs) over an 8-year postoperative period in women who had undergone immediate IBR following risk-reducing mastectomy with bovine ADM (SurgiMend). Methods: This prospective observational single-center analysis involved 34 women at high risk for breast carcinoma. Complications were prospectively recorded during the first year, followed by 4 years of postoperative retrospective chart reviews. Long-term evaluations were done using a questionnaire. Preoperative, 1 year, and 5- to 8-year postoperative PRO assessments were obtained based on results from the BREAST-Q questionnaire. Results: In 56 breasts, complications after a mean of 12.4 months follow-up included implant loss (7.1%), implant change (1.8%), hematoma (7.1%), breast redness (41.1%), and seroma (8.9%). Most breasts (80.3%) were graded Baker I/II, which indicated a low capsular contracture incidence. After a mean of 6.9 years, the total implant explantation rate was 33.9%, and the revision surgery rate was 21.4%. Two cases of breast cancer were reported during the long-term evaluation. BREAST-Q results indicated significantly decreased satisfaction with outcome (P = 0.024). A positive trend regarding psychosocial well-being and declining trend regarding satisfaction with both breast physical- and sexual well-being parameters were reported. Conclusions: The observed complication rates agree with previous findings concerning ADM-assisted IBR. A high demand for revision surgery exists, and PROs remain relatively stable over time.

show abstract

“…Complication rates were divided into major and minor complication rates. Major complication rates, i.e., revision surgeries, were considered a severe adverse event as a significant increase in patient morbidity as well as patient discomfort and a financial burden to the medical system is introduced [ 17 , 20 , 21 ]. Minor complication rates include seroma, requiring and not requiring aspiration, hematoma, and infection.…”

Section: Methodsmentioning

confidence: 99%

Platelet-Rich Plasma (PRP) in Breast Cancer Patients: An Application Analysis of 163 Sentinel Lymph Node Biopsies

Eichler

Baucks

Üner

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Introduction. Literature shows platelet-rich plasma (PRP) to improve overall outcomes in orthopedics, dermatology, ophthalmology, gynecology, and plastic surgery. Data on oncological patients is very limited. Only one publication is available on PRP in breast cancer patients. This work evaluated PRP in sentinel node biopsy procedures for breast cancer patients in terms of complication rates and oncological short-term follow-up. Methods. The evaluated PRP was ACP®, i.e., autologous conditioned plasma by Arthrex®. Between 2015 and 2018, 163 patients were offered to receive an ACP®/PRP injection in their lymph node biopsy site. Recruitment resulted in an approximate one-to-one ratio for analysis. Endpoints were major (revision) and minor (seroma, hematoma, and infection) complications rates as well as distant metastases, local recurrence, and overall survival. Median follow-up was 30 months. Results. Complication rates and oncological follow-up showed PRP to be applicable to use in a sentinel node biopsy scenario in breast cancer patients. There were 0 revisions in the ACP®/PRP group and 1.2% revisions in the control group (not significant). Oncological follow-up showed zero (0) distant metastases and local recurrences as well as a 100% 30-month overall survival. Conclusions. This is the first analysis of ACP®/PRP used in breast cancer patients in a sentinel node biopsy setting worldwide. PRP does not seem to increase rates of local recurrence within this 30-month follow-up time frame. Also, trend towards decreasing complication rates could be shown.

show abstract

A Head to Head Comparison Between SurgiMend® – Fetal Bovine Acellular Dermal Matrix and Tutomesh® – A Bovine Pericardium Collagen Membrane in Breast Reconstruction in 45 Cases

Abstract: Abstract. Background

Cited by 14 publications

References 19 publications

A Retrospective Head-to-head Comparison Between TiLoop Bra/TiMesh® and Seragyn® in 320 Cases of Reconstructive Breast Surgery

A Retrospective Head-to-head Comparison Between TiLoop Bra/TiMesh® and Seragyn® in 320 Cases of Reconstructive Breast Surgery

A Long-term Evaluation of Acellular Dermal Matrix for Immediate Implant-based Breast Reconstruction following Risk-reducing Mastectomy

Platelet-Rich Plasma (PRP) in Breast Cancer Patients: An Application Analysis of 163 Sentinel Lymph Node Biopsies

Contact Info

Product

Resources

About